|
Researchers say ingredients of Voltaren are as likely to cause heart problems as drugs with Cox-2 inhibitors
(IRN News Via Thomson Dialog NewsEdge) Arthritis New Zealand is calling for a review of Cox-2 inhibitors in light of new information about Voltaren.
The organisation wants a rethink after research has found ingredients in the alternative drugs to Cox-2 inhibitors, such as Voltaren, can cause heightened risk of heart attacks.
A study in the American Medical Association Journal has raised concerns about the effects of the active ingredient diclofenac, which is found in Voltaren and Cataflam.
In similar doses to Cox-2 inhibitor medications, diclofenac drugs were found to increase the chance of heart attack by 40 percent.
Arthritis New Zealand CEO Roger Sowry says this should cause PHARMAC and Medsafe to review the status of Cox-2 inhibitors, which are not allowed to be advertised and do not get any funding because of the increased risk of heart attack or stroke they bring.
He says in light of this new information about Voltaren there needs to be a level playing field. Mr Sowry says Cox-2 drugs are crucial for arthritis patients who often use them as the last line of defence against pain.
In February 2005, the New Zealand Ministry of Health issued a strong warning on Cox-2 painkillers, saying the increased risk of heart attack and stroke outweighs the benefits.
Vioxx was withdrawn in 2004 - but the 2005 warning also covered other Cox-2 inhibitors, including Celebrex, and ArCoxia.
America's influential Food and Drug Administration says Cox-2 drugs "significantly increase" the risk of a heart attack or stroke, and although it stopped short of a complete ban, the FDA's advisory panel agreed there was a need for the drugs to have a "black box warning."
Cox-2 inhibitors are among the group of analgesics called non-steroidal anti-inflammatory drugs (NSAIDs), which also includes aspirin, and ibuprofen (Nurofen).
Copyright 2006 IRN News
[ Back To TMCnet.com's Homepage ]
|